anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
A method of mercury-free photochemical micro-/nano-encapsulation of an active material is a process for obtaining micro-/nano-capsules by means of curing by UV LED radiation at ambient or even cold temperatures. A stirrer photo-reactor made from glass or transparent plastics can be used but mixed flow reactor could be also employed. Appropriate mixing is sufficient to expose all droplets, which contain an active material surrounded by curable-shell materials in the emulsion to the LED radiation. Using the optimum light intensities and reactions&#39; times is critical for encapsulating the active material with a high efficiency and producing a high quality micro-/nano- capsules, Solar monochromator device can also be used as long as it generate the same radiation with a narrow/single wavelengths as the LED device. Light emitted diode (LED) is a mercury-free UV radiation source with a long operating life time and an instant ON-Off. it has a high efficiency, a very low cooling requirements and cost-efficient in photochemical encapsulation. It reduces the time of microencapsulation from 6 hours to a less than 5 minutes. It has a significant decrease in manufacturing cost, waste-water, unconverted monomers, and leftover active phase change material (PCM) compared to other methods. Conversion of more than 90% of monomers can be achieved, and encapsulation efficiency can reach 100% at optimum conditions. This is in addition to the ability of this invented technology for encapsulate volatile and heat sensitive active materials at ambient as well as low temperatures. Normal glass or transparent plastics can be used as a reactor material. Only the matched useful wavelength radiation is emitted by LED without having other wavelengths which might have a bad impact on the encapsulation process.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide genes functioning in the development and differentiation of a mammalian immune system and/or the control of physiological function.  &lt;P&gt;SOLUTION: The nucleic acid derived from primates and encoding various monocyte proteins, reagents related to the same (including specific antibodies) and purified proteins are described. The method for using the reagents and a related diagnostic kit are also provided. The disclosure aims at a composition associated with the genes found in the monocyte which is a cell functioning in an immune system. These genes function in the development and differentiation of the mammalian immune system, and/or controlling of the physiological functions. In the disclosure, especially the nucleic acids, proteins, antibodies and methods for using them are provided.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
Correlations stored in databases and an individual&#39;s DNA test results are used to recommend an activity to the individual to enhance expression of a gene that influences a phenotypical health trait. The databases include a pathway database, and an activity database. The pathway database stores gene correlations that indicate correlations between genes and biochemical pathways. The biochemical pathways influence the individual&#39;s phenotypical health traits. The activity database stores activity correlations that indicate correlations between human activities and biochemical pathway effects. The DNA test result includes gene indicators indicating the individual&#39;s genetic makeup. The pathway database and the gene indicators are used to identify the individual&#39;s influenced biochemical pathways. The activity database is used to identify the activity because the activity affects at least one of the influenced biochemical pathways. The activity is recommended to the individual.
PROBLEM TO BE SOLVED: To obtain a medicinal agent useful as an interleukin-6 production inhibitor, bone resorption inhibitor or antiosteoporotic agent, containing a thiazole compound having a specific structure as active ingredient. SOLUTION: This medicinal agent contains, as active ingredient, a thiazole compound of the formula (R&lt;1&gt; is H, a (substituted) amino, etc.; R&lt;2&gt; is a (substituted) aryl; R&lt;3&gt; is H, a halogen, etc.) or a pharmaceutically permissible salt thereof, e.g. 2-amino-4-(4-chlorophenyl)-5-methylthiazole. The compound of the formula is obtained, for example, by the following process: bromine is dripped into a 4&#39;-chloropropiophenone&#39;s dichloromethane solution to carry out a reaction; after the reaction, the solvent is distilled off the reaction mixture, and ethanol is added to the resultant residuals into a solution, an aqueous thiourea solution is then added to the above solution followed by agitation, and the mixed solution is adjusted to pH7 and the reaction product is purified by silica gel column chromatography.
This idea represents a method for incorporation of a therapeutic molecule, preferably a protein or a growth factor, into a biodegradable scaffold, specifically one that is made of a foam nonwoven composite. The process utilizes a solvent preferably tertiary butanol to facilitate the infiltration of the particles of the therapeutic agent into the porous matrix of the scaffold. In the case of small molecules, such as a p38 kinase inhibitor, the drug is dissolved directly in sterile filtered t-butanol and a given amount is pipetted aseptically onto the pre-sterilized scaffold. The solution is readily adsorbed into the polymer matrix. The solution is readily frozen to allow minimal interaction with the polymer scaffold thereby protecting the scaffold&#39;s internal matrix. The solvent is then aseptically removed by lyophilization.
PURPOSE:To obtain a bathing agent having the fragrance of wine and effective in keeping the warmth of body, making fair skin, recovering from fatigue, etc., by drying the squeezing residue of wine-brewing process at a specific temperature to attain a specific water content and sealing the dried residue in a water-permeable bag. CONSTITUTION:Squeezing residue generated in a wine-brewing process (hereinafter called as wine residue) (e.g. the squeezing residue generated in the squeezing step after the completion of fermentation in the case of red wine or the squeezing residue generated in the squeezing step before the fermentation process in the case of white wine) is dried at &lt;=40 deg.C to obtain a dried product having a water content of &lt;=15% (preferably &lt;=10%). The dried product is sealed in a water-permeable bag (e.g. small bag made of cotton, nonwoven cloth, paper, etc., preferably a heat-sealable nonwoven cloth). Since there is no contamination of bath water with insoluble component of the wine residue, the unpleasant feeling caused by the adhesion of the component to the body can be prevented.
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to ophthalmology. For ultraviolet (UV) cross-linking of the cornea with progressive keratectasia in the patients with developed far-reaching keratoconus and iatrogenic ectasia after refractive interventions preliminary revealing the most thin section of cornea according to patient&#39;s pachymetric chart and area of ectasia. De-epithelialisation of cornea in 8.5 mm zone, saturation of de-epithelised cornea and soft contact lens with 0.1 % aqueous solution of riboflavin. Riboflavin-saturated contact lens is then trepaned to produce a disc with diameter of 3–5 mm and thickness of 120 mcm, which is perforated. Thereafter, the disc is placed on the cornea so that its center coincides with the apex of the cone on the basis of the data of topographic pachymetry and keratotopography of the patient. Ultraviolet irradiation is performed capacity of 3 mW/cm2for 30 minutes, or 9 mW/cm2for 10 minutes, or 18 mW/cm2for 5 minutes.EFFECT: method provides a therapeutic effect and protection of deep layers of the cornea by local thickening in a zone of maximum thinning and distribution of radiation at the same depth throughout the entire surface of the cornea, access of oxygen to the cornea during the procedure, as well as possibility of the patients with a thin cornea treatment by the cross-linking method.1 cl, 3 ex
PURPOSE:To upgrade selective urea adsorptivity and to increase adsorptive power by constituting the outside layer of hollow micro-spherical bodies of a urea permeable polymer and constituting the inside layer thereof of a polymer contg. a specific polyoxyalkylene glycol deriv. CONSTITUTION:The radical polymerizable polyoxyalkylene glycol deriv. expressed by formula I or formula II (n is 2-5 integer, m is &gt;=3 integer, R is H, methyl group, R&#39; is H, hydrocarbon group of 1-10C) is dissolved in the inside water layer of a W/O/W type emulsion. For example, an oil soluble radical polymerizable monomer is used as an oil layer therewith and is subjected to an emulsion polymn., by which the hollow micro-spherical bodies are produced. The inside layer of such hollow micro-spherical bodies is constituted of the polymer of the above-mentioned polyoxyalkylene glycol and the outside layer is mainly constituted of the polymer of the oil soluble radical polymerizable monomer.
1483783 Saponin-containing materials WADLEY RESEARCH INSTITUTE &amp; BLOOD BANK JK AND SUSIE L 24 Oct 1974 [10 Dec 1973] 46042 74 Heading A5B [Also in Division C2] Haemolytic saponin-containing material which has been extracted from plant tissue is detoxified by separating from an aqueous solution thereof constituents which are toxic to microbial organisms and which have an apparent mol. wt. in said solution of up to 600. Preferably there is used a gel or a filter membrane of mean pore diameter 11-24 which passes the toxins but retains the saponins. An ultrafiltration apparatus for this is described and illustrated. The solvent for the aqueous solution may be distilled water or normal saline solution. Specified saponin sources are soap bark (Quillaja Saponaria), soap berry, panama wool and licquorice. Saponins mentioned are glycosides of diosgenin and of quillaic acid. The purified saponin is used to haemolyse red blood cells in a blood sample which may then be subjected to a bacteria cultering process.
Methods, systems, and computer-readable mediums for generating, by an artificial intelligence engine, an alignment plan capable of enabling, during a treatment session, the aligning of a user&#39;s body. The method comprises generating machine learning models trained to identify alignment plans. The method also comprises receiving treatment data that comprises a first position of the user&#39;s body, aspects of a treatment plan, and one or more attributes of the user. The method further comprises generating the alignment plan by using the machine learning models. The generating is based on at least the aspects of the treatment plan and at least one of the one or more attributes of the user. The alignment plan may comprise a target position of the user&#39;s body and one or more elements for adjusting the user&#39;s body from the first position to the target position. The method also comprises transmitting the plan to a computing device.
A motion analytics system has a therapy boot, a camera for capturing motion of the therapy boot, and an external computing device communicatively coupled to the camera and the therapy boot. The therapy boot includes a foot portion, a shank portion, and a sole portion. The shank portion is disposed adjacently above the foot portion. The sole portion is disposed under the foot portion and includes sensors configured to detect motion of a user&#39;s foot. The external computing device receives motion data from the sensors and performs a data analytics method. The method includes organizing the received data; filtering at least a portion of the organized data through a frequency-based signal processing filter to remove background noise and interference therefrom; determining analytical data associated with one or more foot factors based on the filtered data; and categorizing the determined analytical data to provide context and insight about the user&#39;s motion.
PURPOSE:To obtain a collagen decomposition promoter capable of inducing decomposition of the collagen matrix of a connective tissue excessively accumulated in the tissue and useful for therapy of fibrosis diseases. CONSTITUTION:This collagen decomposition promoter contains one or more kinds of HGFs(hepatocyte growth factor) as the active components. As the HGFs, e.g. HGF is used. HGF can be obtained by extracting an organ, hemocyte, plasma, serum, etc., of a mammal and purifying it or by culturing a primary culture cell or an established cell respectively producing HGF and conducting separation and purification from the products or by a gene engineering technique. The HGFs have a therapeutic effect on fibrosis diseases including arterial sclerosis, chronic glomerular nephritis, dermal keloplasty, progressive systemic sclerosis, fibroid lung, hepatic fibrosis, cystic fibrosis, chronic graft versus host diseases, hidebound diseases (local or systemic), Peyronie&#39;s disease, penile fibrosis, urethrostenosis after cystoscopy, internal adhesion after surgical operation, myelofibrosis and idiopathic retroperitoneal fibrosis.
FIELD: medicine.SUBSTANCE: invention refers to medicine and can be used for producing and culturing fibroblast-like cells from a newborn&#39;s umbilical cord. That is ensured by umbilical cord sampling in healthy females following the delivery of the cesarean section. Umbilical cord is washed three times with sterile Hanks solution with an antibiotic of blood clots and mucus. Blood vessels are removed. Remaining fabric is ground, material is transferred into centrifuge tubes and poured with 0.2 % collagenase solution. Tubes are placed in a temperature shaker at a temperature of +37 °C, rotation speed 100 rpm for 16 hours. Content is filtered into new test tubes. Sterile 0.02 % Versene solution is introduced into them at ratio of 1:1 and centrifuges are tested in a cold centrifuge for 20 minutes. Cell pellet is resuspended in complete nutrient medium and number of recovered viable cells is counted. Cells are inoculated into a culture flask. Culturing is carried out in COincubator and medium change every 5 days of cultivation. When cell monolayer confluence reaches 80 %, cells are re-crossed at ratio of 1:2.EFFECT: invention enables to obtain fibroblast-like cells without the risk of contaminated opportunistic flora.1 cl, 1 tbl
The invention relates to a quick-response nitric oxide near-infrared probe, and preparation and biological application thereof, and belongs to the field of organic fluorescent probes, wherein the structure of the probe is shown as a formula (I). The invention designs and synthesizes a near-infrared nitric oxide probe with quick response. The probe has near infrared emission in response to NO. In vitro experimental studies show that the probe and NO react quickly. Under physiological conditions (pH 7.4), the probe is stable and has high sensitivity, selectivity and interference resistance to NO. Biological experiment research shows that the probe can be applied to detection of the level of endogenous NO in cells, and can also be applied to detection of the level of NO in PD cells and drosophila brain models. These results show that the probe has high specificity, selectivity and stability, and may be applied to early diagnosis of Parkinson&#39;s disease in the future.
PURPOSE:To obtain the titled preparation for treating peptic ulcer, having raised disintegration and dispersibility and high utility as drug, containing an aluminum salt of sucrose sulfuric acid ester and polyethylene glycol. CONSTITUTION:A preparation containing an aluminum salt of sucrose sulfuric acid ester and polyethylene glycol. Disintegration and dispersibility of aluminum salt of sucrose sulfuric acid ester (A for short) are raised by the use of polyethylene glycol and utility as drug is also elevated. Since A is insoluble in water, disintegration and dispersibility are raised to give effective bond to an ulcer site. The amount of the polyethylene glycol added is &gt;=0.1 (W/W) based on A. When the preparation is orally administered, A is effectively bonded to the ulcer site.
PURPOSE:To obtain a safe pure vegetable beautifying cosmetic without containing a chemical substance, by adding water or hot water to a tuberous root of KONJAK (devil&#39;s-tongue), as necessary, heated, dried material thereof or a mixture thereof with mugwort, gelatinizing the resultant blend, applying the obtained paste to the skin and washing the paste with water. CONSTITUTION:Water or hot water is added to (A) a tuberous root of KONJAK or dried material thereof, (B) heated tuberous root of the KONJAK or dried material thereof or (C) a mixture prepared by mixing the above-mentioned components (A) and (B) with mugwort to provide a pasty form and afford a pure vegetable cosmetic capable of safely beautifying the skin without irritation to the skin, since chemical substances are not contained at all. If the above- mentioned cosmetic is applied to respective parts (face, body, hands, legs, etc.) of the skin, it is well adsorbed on the skin so that enzymic proteins, etc., contained in the paste may capture stain and dirt latent in the skin. The paste is then washed with water to remove all the stain and dirt to clean the skin. Furthermore, the mugwort has unique beautifying action on the skin in addition to germicidal and preservative effects thereof.
The invention discloses a health product for improving nutritional anemia prepared from plant extracts and ox blood extracts. Preferably, the weight ratio of the ox blood extracts to the plant extracts is 1:1. Animal tests prove that the health product can obviously increase the body weight of a rat suffering from iron deficiency anemia, increase a haemoglobin content of the rat suffering from iron deficiency anemia and decrease free protoporphyrins in red blood cells. Tests on acute toxicity and undue toxicity show that the toxic reaction dosage of the health product is obviously increased. The invention also provides a method for preparing the health product. The preparation method has the advantages of simple extraction process, no chemical pollution, no generation of industrial &#39;three wastes&#39; and wide industrial application prospect.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a highly effective anti-inflammatory/analgesic composition for external application by increasing skin permeability of a nonsteroidal anti-inflammatory/analgesic agent.  &lt;P&gt;SOLUTION: The anti-inflammatory/analgesic composition for external application contains the nonsteroidal anti-inflammatory/analgesic agent and a starch powder. The nonsteroidal anti-inflammatory/analgesic agent is used for chronic rheumatism, osteoarthritis and acute and chronic musculoskeletal pains but generally has a side effect such as gastrointestinal injury. Therefore, various formulations other than oral agents such as external preparations and suppositories have been developed and used for medical practice. The present invention solves the problem associated with the external preparations wherein satisfactory effects could not be achieved due to a marked deterioration in the skin permeability of the drug induced by a biological barrier effect of keratin.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
PURPOSE: To obtain a seed treating agent contg. a salt of vitamin B1 in the form of fine powder, promoting the growth of a plant and capable of enhancing the yield of the objective product. CONSTITUTION: This seed treating agent contains a salt of vitamin B1 , preferably mononitrate in the form of fine powder or further contains a nonbactericidal fungicide. The salt preferably has &lt;=20μm average particle size. The fungicide is preferably a phthalimide such as N-trichloromethylthiotetrahydrophthalimide, a thiuram sulfide such as tetramethylthiuram disulfide or a thiocarbamoyl fungicide. This treating agent is preferably applied to seed before planting at 0.3-4g/kg concn.
PURPOSE: To induce rapid miosis while carrying out 24hr control of intraocular pressure of patients undergoing extracapsular cataract extraction by adding two kinds of miotic medicines to patient eye. CONSTITUTION: A first miotic medicine comprising a compound of formula I (R and R&#39; are each a 1-5C alkyl; X&lt;-&gt; is an anion such as halogen), e.g. acetylcholine in which R and R&#39; are each methyl and X is chlorine is topically applied to the eye and a second miotic medicine comprising a compound of formula II [(n) is 0-3], e.g. carbachol in which R&lt;2&gt; s are all methyl; (n) is 0 and X is chlorine is topically applied to the eye and rapid miosis is induced while controlling intraocular pressure during intraocular operation. Dried powder of frozen and dried substance (e.g. mannitol), dried powder of the first miotic agent and the second miotic medicine dissolved in isotonic aqueous salt are each housed in a separated compartment and both medicines are mixed and applied when applied.
A motion state monitoring system, a training support system, a motion state monitoring method, and a program capable of suitably managing measurement results according to an attaching direction of a sensor are provided. A motion state monitoring system according to the present disclosure monitors a motion state of a target part of a subject&#39;s body. The motion state monitoring system includes an acquisition unit, an attaching direction detection unit, and a control processing unit. The acquisition unit acquires sensing information of a sensor attached to the target part. The attaching direction detection unit detects an attaching direction of the sensor. The control processing unit outputs information related to the sensing information in association with the attaching direction.
A system for weight loss or weight management of a person may include a monitoring unit and remote computing system. The monitoring unit includes a transducer arranged to generate a signal representative of the patient&#39;s weight. It further includes a processor operatively coupled to the transducer and to a memory device. Further, an output device and an input device are operatively coupled to the processor. The memory device is programmed with a set of instructions causing the processor to cooperate with the output device to present questions directed toward weight loss and to cooperate with the input device to receive answers to the questions. The remote computing system is in communication with the monitoring unit. The remote computing system is programmed to receive the answers provided by the person and to receive the signal representative of the person&#39;s weight. The remote computing system generates an alert on the basis thereof.
NEW MATERIAL:The compound of formula I (R&lt;1&gt; is phenyl or thienyl; R&lt;2&gt; is lower alkyl, phenyl-substituted lower alkyl, lower alkanoyl or benzoyl; X is halogen; m is 1 or 2; n is 0 or 1) or its salt. EXAMPLE:2-(4-Chlorophenyl)-4-phenyl-5-(methylthiomethyl)imidazole. USE:An anti-inflammatory, analgesic and/or antipyretic. It has low toxicity, and is useful for the remedy or mitigation of the inflammation of the skeletal muscle joints such as knee joint, humeral joint, etc., and the inflammation of other organs such as rheumatism, gout, etc. PREPARATION:The compound of formula I wherein n=0 can be prepared e.g. by reacting the compound of formula II (Y is reactive group) with the compound of formula R&lt;2&gt;SZ (Z is H or alkali metal) in a solvent if necessary in the presence of a base. Another compound of formula I wherein n=1 can be produced by oxidizing the above product with an oxidizing agent in a solvent.